0001367644-21-000008.txt : 20210209 0001367644-21-000008.hdr.sgml : 20210209 20210209172357 ACCESSION NUMBER: 0001367644-21-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210208 FILED AS OF DATE: 20210209 DATE AS OF CHANGE: 20210209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kramer Robert CENTRAL INDEX KEY: 0001380956 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 21607948 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 wf-form4_161290942063298.xml FORM 4 X0306 4 2021-02-08 0 0001367644 Emergent BioSolutions Inc. EBS 0001380956 Kramer Robert 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 1 1 0 0 President and CEO Common Stock 2021-02-08 4 M 0 32397 30.86 A 171607 D Common Stock 2021-02-08 4 S 0 32397 120.03 D 139210 D Common Stock 2021-02-08 4 M 0 13000 30.63 A 152210 D Common Stock 2021-02-08 4 S 0 13000 120.03 D 139210 D Employee Stock Options (Right to Buy) 30.86 2021-02-08 4 M 0 32397 120.03 D 2023-02-28 Common Stock 32397.0 0 D Employee Stock Options (Right to Buy) 30.63 2021-02-08 4 M 0 13000 120.03 D 2024-02-27 Common Stock 13000.0 19638 D Consists of an option granted on 3/1/2016 under the company's stock incentive plan as amended and restated. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20. Consists of an option granted on 2/28/2017 under the company's stock incentive plan as amended and restated. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.19. The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. /s/ S. Scott Lieberman, Attorney-in-fact 2021-02-09